new glp-1 retatrutide ๐๐ฅ Retatrutide: The Most Powerful Weight-Loss Drug Yet? ๐งฌ๐ Phase 3 clinical results are turning heads retatrutide, a next-generation triple-agonist targeting GLP-1, GIP and glucagon receptors, is showing unmatched levels of Diagram showing the mechanism of
Description
Salas Whalen sees this in her practice

Nutritional priorities to support GLP -1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society

Novel Functional, Health, and Genetic Determinants of Cognitive Terminal Decline: Kuakini Honolulu Heart Program/Honolulu-Asia Aging Study

[DOI] [PMC free article] [PubMed] [Google Scholar] 23.Sofat R., Hingorani A.D., Smeeth L., Humphries S.E., Talmud P.J., Cooper J., Shah T., Sandhu M.S., Ricketts S.L., Boekholdt S.M., et al
This is my understanding and Im hoping you can add clarity or potentially make a post addressing these concerns

A very small number of people might develop a rare risk eye condition called diabetic retinopathy
